ナイジェリアの国家ナトリウム削減プログラムの実施とスケールアップの評価 (NaSS)
The NaSS aims to assess the extent to which the SHAKE program is implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC) using a type III hybrid, mixed method study design.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
The Nigerian Agency for Food and Drug Administration and Control (NAFDAC) is leading implementation and scale-up of a national sodium reduction program with other national, state, and international agencies using the WHO's "Best Buy" SHAKE package (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote healthy eating). SHAKE provides evidence-based recommendations for population-wide sodium reduction interventions for hypertension prevention and control.
The Nigeria Sodium Study will support this program's implementation and scale-up by evaluating the extent to which the program is implemented using a type III hybrid, mixed methods study design through repeated: 1) stakeholder interviews, 2) populations surveys, and 3) retail surveys. Implementation research methods will be used during adaptation, planning, and initial implementation for baseline (Wave 1) and follow-up Waves 2 and 3) assessments. A dietary sources of sodium study will also be performed at baseline and Wave 3 follow-up to target/track sodium reduction efforts according to local context and culture. Food retail surveys over the study period will capture novel data on packaged, unpackaged, and informal restaurant/hawker food through the international FoodSwitch program, which combines a consumer facing tool with crowdsourcing to better define Nigeria's food supply.
Investigators will use the Exploration, Preparation, Implementation and Sustainment (EPIS) framework throughout both phases. The formative research period will include Exploration and Preparation, when investigators will perform quantitative and qualitative measures of key process indicators, relevant contextual factors informed by CFIR, and relevant Proctor implementation outcomes, acceptability, feasibility and appropriateness. As implementation is started, investigators will use the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework, including implementation outcomes (feasibility, fidelity, adoption, acceptability, and cost) and contextual factors associated with the Implementation and Sustainment phases.
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Valerie Graham, MPH
- 電話番号:618-559-5514
- メール:grahamv@wustl.edu
研究場所
-
-
-
Gwagwalada、ナイジェリア
- 募集
- University of Abuja Teaching Hospital
-
コンタクト:
- Dike Ojji
-
Kano、ナイジェリア
- 募集
- Aminu Kano Teaching Hospital
-
コンタクト:
- Dike Ojji
-
-
Ogun State
-
Abeokuta、Ogun State、ナイジェリア
- 募集
- Federal Medical Centre
-
コンタクト:
- Dike Ojji
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Adults will be enrolled as a single household representative from 3 states (Federal Capital Territory, Kano, and Ogun) of Nigeria.
説明
Inclusion Criteria:
- Male and female adults (aged 18 to 69 years)
- Willingness to participate
- Permanent residents (a person who has been in the household for at least 6 months) of the study area
- Ability to provide informed consent
Exclusion Criteria:
- Individuals who are unable to provide informed consent
- Pregnant women, and those who are breastfeeding and/or women menstruating at the time of collection
- Cognitively impaired adults
- Those with known history of heart or kidney failure, stroke, liver disease
- Those who recently began therapy with diuretics (less than two weeks)
- Any other conditions that would make 24-hour urine collection difficult
- Individuals who are not yet adults (minors): i.e. infants, children, or teenagers <18 years old
- Prisoners or other detained individuals
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:ECOLOGIC_OR_COMMUNITY
- 時間の展望:CROSS_SECTIONAL
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
Wave 1
Participants will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a STEPs survey, 24-hour and spot urine assessments, blood sample collection for fatty acid estimation, and four (4) 24-hour dietary recalls (n=450). |
The SHAKE (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote health eating) package is a WHO Best Buy and is recently implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC). |
|
Wave 2
Participants will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a STEPs survey and 24-hour and spot urine assessments (n=450). |
The SHAKE (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote health eating) package is a WHO Best Buy and is recently implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC). |
|
Wave 3
Participants will be enrolled as a single adult household representative from 3 states (Federal Capital Territory, Kano, Ogun) of Nigeria to complete a STEPs survey, 24-hour and spot urine assessments, and four (4) 24-hour dietary recalls (n=450). |
The SHAKE (Surveillance of salt intake, Harness industry, Adopt standards for labelling and marketing, Knowledge to empower consumers, and Environments to promote health eating) package is a WHO Best Buy and is recently implemented within Nigeria by the Nigerian Agency for Food and Drug Administration and Control (NAFDAC). |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
ベースライン (第 1 波) からフォローアップ (第 3 波) までの 24 時間尿中ナトリウムの変化
時間枠:ベースライン (ウェーブ 1) からフォローアップ (ウェーブ 3 [ベースラインから推定 36 か月後])
|
ベースライン (ウェーブ 1) からフォローアップ (ウェーブ 3 [ベースラインから推定 36 か月後])
|
|
|
Change in mean population sodium intake from baseline (Wave 1) to follow-up (Waves 2 and 3).
時間枠:Baseline (Wave 1) to follow-up (Wave 2 [estimated 18 months post-baseline] and Wave 3 [estimated 36 months post-baseline)
|
Change in mean population sodium intake by age, sex, state, rurality, and presence of hypertension subgroups from baseline to Wave 2 and Wave 3 follow-up |
Baseline (Wave 1) to follow-up (Wave 2 [estimated 18 months post-baseline] and Wave 3 [estimated 36 months post-baseline)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in overall and relative amount of dietary sources of sodium from baseline (Wave 1) to follow-up (Wave 3)
時間枠:Baseline (Wave 1) to follow-up (Wave 3 [estimated 36 months post-baseline)
|
Change in overall and relative amount of dietary sources of sodium (e.g., inherent in food, added during preparation, added at the table, added outside the home) by age, sex, state, rurality subgroups from baseline (Wave 1) to follow-up (Wave 3) based on the dietary sources of sodium study instruments. |
Baseline (Wave 1) to follow-up (Wave 3 [estimated 36 months post-baseline)
|
|
Changes in self-reported knowledge, attitudes, and behavior about harms associated with excess sodium intake from baseline (Wave 1) to follow-up (Wave 3)
時間枠:Baseline (Wave 1) to follow-up (Wave 3 [estimated 36 months post-baseline)
|
Changes in self-reported knowledge, attitudes, and behavior about harms associated with excess sodium intake by age, sex, state, rurality subgroups from baseline (Wave 1) to follow-up (Wave 3) using based on the STEPS survey instrument. |
Baseline (Wave 1) to follow-up (Wave 3 [estimated 36 months post-baseline)
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in mean population systolic and diastolic blood pressure from baseline (Wave 1) to follow-up (Waves 2 and 3).
時間枠:Baseline (Wave 1) to follow-up (Wave 2 [estimated 18 months post-baseline] and Wave 3 [estimated 36 months post-baseline)
|
Change in mean population systolic and diastolic blood pressure by age, sex, state, rurality subgroups. |
Baseline (Wave 1) to follow-up (Wave 2 [estimated 18 months post-baseline] and Wave 3 [estimated 36 months post-baseline)
|
|
Change in blood pressure lowering medication use
時間枠:Baseline (Wave 1) to follow-up (Wave 2 [estimated 18 months post-baseline] and Wave 3 [estimated 36 months post-baseline)
|
Change in blood pressure lowering medication use by age, sex, state, rurality subgroups. |
Baseline (Wave 1) to follow-up (Wave 2 [estimated 18 months post-baseline] and Wave 3 [estimated 36 months post-baseline)
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Mark D Huffman, MD, MPH、Washington University School of Medicine
- 主任研究者:Dike B Ojji, MD, PhD、University of Abuja Teaching Hospital
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- NaSS_202306135
- UG3HL152381 (米国 NIH グラント/契約)
- UH3HL152381 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data will be shared through NHLBI BioLINCC.
IPD 共有時間枠
Data will be available within 1 year of study conclusion.
IPD 共有アクセス基準
Access to study data will be managed through NHLBI BioLINCC
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- ANALYTIC_CODE
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。